Orthopaedic Nurses Certification Board (ONCB) Metabolic/Inflammatory/Tumors Practice Exam

Bisphosphonates are indeed a primary treatment option for osteoporosis. These medications work by inhibiting osteoclast-mediated bone resorption, thus helping to increase bone density and reduce the risk of fractures. Bisphosphonates are typically prescribed for both the prevention and treatment of osteoporosis, especially in postmenopausal women and individuals with a history of fractures.

The role of bisphosphonates is critical in managing osteoporosis, as they target the underlying problem of diminished bone density. Commonly prescribed bisphosphonates include alendronate, risedronate, and zoledronic acid. They are particularly effective because they not only help to build bone but also have a long-term therapeutic effect, often continuing to work in the body even after treatment has stopped.

In contrast, chemotherapy is aimed at treating cancer and does not address bone density issues. Antibiotics target bacterial infections, and insulin therapy is primarily used to manage diabetes, neither of which play a role in treating osteoporosis. This distinction underscores the importance of selecting a treatment that specifically addresses the mechanisms of osteoporosis, leading to the conclusion that bisphosphonates are indeed the appropriate choice for treating this condition.